Shields Pharma
A private biotech developing cGMP‑grade psychedelic medicines and contract analytical services for mental health and addiction.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A private biotech developing cGMP‑grade psychedelic medicines and contract analytical services for mental health and addiction.
Mental HealthAddictionPain
Technology Platform
Integrated cultivation of Psilocybe cubensis, proprietary extraction/purification of psychedelic APIs, and cGMP‑compliant analytical testing (USP, ICH Q3D, etc.) for drug development and contract services.
Opportunities
Rapidly expanding psychedelic therapeutics market and demand for cGMP‑grade APIs present strong growth potential for both product development and contract testing services.
Risk Factors
Regulatory uncertainty, clinical trial success, and scaling manufacturing while maintaining stringent quality standards are the primary risks.
Competitive Landscape
Competes with companies like COMPASS Pathways, MindMed, and ATAI Therapeutics; differentiation stems from its integrated cultivation‑extraction‑analytics platform and contract testing revenue stream.